Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Raymond A. Ng
Observed name:
Raymond Ng
Institution:
Olema Pharmaceuticals (United States)
Observed institution:
Olema Pharmaceuticals (United States)
ORCID:
0000-0002-2815-7718
Observed ORCID:
0000-0002-2815-7718
OpenAlex ID:
A5039590241
An update on the discovery and development of reversible covalent inhibitors
2023
·
Faridoon
, Raymond Ng
, et al.
·
Medicinal Chemistry Research
·
105
PDF
Discovery of Palazestrant (OP-1250), a Potent and Orally Bioavailable Complete Estrogen Receptor Antagonist (CERAN) and Selective Estrogen Receptor Degrader (SERD)
2025
·
Raymond A. Ng
, Susanna Barratt
, et al.
·
ACS Omega
·
5
PDF
Abstract 2949: Palazestrant, a CERAN, in combination with OP-3136, a KAT6 inhibitor, synergistically downregulates cell proliferation and metastasis related gene signatures.
2026
·
Susanna A. Barratt
, Gopinath S. Palanisamy
, et al.
·
Cancer Research
Abstract 2950: Palazestrant directly recruits the corepressor protein NCoR1 in vitro leading to complete antagonism of estrogen receptor alpha.
2026
·
Susanna A. Barratt
, Guadelupe Peña
, et al.
·
Cancer Research
Show more works
View as search
Works count:
4
Citation count:
110
H-index:
2
I10-index:
1
Year
Topic
Type